210 related articles for article (PubMed ID: 25894719)
1. Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe.
Yang BB; Morrow PK; Wu X; Moxness M; Padhi D
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1199-206. PubMed ID: 25894719
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2024 Mar; 41(3):991-1009. PubMed ID: 38180721
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2023 Nov; 40(11):4889-4906. PubMed ID: 37707674
[TBL] [Abstract][Full Text] [Related]
4. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects.
Bush J; Kawakami K; Muniz R
BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742
[TBL] [Abstract][Full Text] [Related]
5. Performance of the pegfilgrastim on-body injector as studied with placebo buffer in healthy volunteers.
Joshi RS; Egbuna OI; Cairns AS; Friedman MJ; Abosaleem B; Reiner MT; Morrow PK
Curr Med Res Opin; 2017 Feb; 33(2):379-384. PubMed ID: 27819161
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.
Hu C; Ji B; Hu X; Yang C; Sun W; Zhao X; Li L; Li X; Zhang L
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):291-298. PubMed ID: 32567217
[TBL] [Abstract][Full Text] [Related]
7. An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.
Shin KH; Lim KS; Lee H; Jang IJ; Yu KS
Invest New Drugs; 2014 Aug; 32(4):636-43. PubMed ID: 24468886
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults.
Tomaszewska-Kiecana M; Dryja A; Ullmann M; Petit-Frere C; Illes A; Dagres C; Monnet J
Expert Rev Clin Immunol; 2023 Apr; 19(4):447-455. PubMed ID: 36789991
[TBL] [Abstract][Full Text] [Related]
9. Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers.
Zheng Y; Abuqayyas L; Megally A; Fuhr R; Sałapa K; Downie J; Colice G
Clin Ther; 2021 Jan; 43(1):142-155.e5. PubMed ID: 33380362
[TBL] [Abstract][Full Text] [Related]
10. Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers.
Buchner A; Lammerich A; Abdolzade-Bavil A; Müller U; Bias P
Curr Med Res Opin; 2014 Dec; 30(12):2523-33. PubMed ID: 25251999
[TBL] [Abstract][Full Text] [Related]
11. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males.
Wynne CJ; Ellis-Pegler RB; Waaka DS; Schwabe C; Lehle M; Heinzmann D; Mangat R; Li C; Dick AE; Cranshaw NA; Lum BL
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1079-87. PubMed ID: 24057039
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
Whitworth JM; Matthews KS; Shipman KA; Numnum TM; Kendrick JE; Kilgore LC; Straughn JM
Gynecol Oncol; 2009 Mar; 112(3):601-4. PubMed ID: 19110303
[TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
Waller CF; Tiessen RG; Lawrence TE; Shaw A; Liu MS; Sharma R; Baczkowski M; Kothekar MA; Micales CE; Barve A; Ranganna GM; Pennella EJ
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1087-1095. PubMed ID: 29671069
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy Subjects.
Finck B; Tang H; Civoli F; Hodge J; O'Kelly H; Vexler V
Adv Ther; 2020 Oct; 37(10):4291-4307. PubMed ID: 32789809
[TBL] [Abstract][Full Text] [Related]
16. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial.
McAllister L; Anderson J; Werth K; Cho I; Copeland K; Le Cam Bouveret N; Plant D; Mendelman PM; Cobb DK
Lancet; 2014 Aug; 384(9944):674-81. PubMed ID: 24881803
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
André N; Kababri ME; Bertrand P; Rome A; Coze C; Gentet JC; Bernard JL
Anticancer Drugs; 2007 Mar; 18(3):277-81. PubMed ID: 17264759
[TBL] [Abstract][Full Text] [Related]
18. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.
Yang BB; Savin MA; Green M
Chemotherapy; 2012; 58(5):387-98. PubMed ID: 23296266
[TBL] [Abstract][Full Text] [Related]
19. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
Vogel CL; Wojtukiewicz MZ; Carroll RR; Tjulandin SA; Barajas-Figueroa LJ; Wiens BL; Neumann TA; Schwartzberg LS
J Clin Oncol; 2005 Feb; 23(6):1178-84. PubMed ID: 15718314
[TBL] [Abstract][Full Text] [Related]
20. Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers.
Zhang W; Tyrrell H; Ding HT; Pulley J; Boruvka A; Erickson R; Abouhossein M; Ravanello R; Tang MT
Adv Ther; 2021 May; 38(5):2418-2434. PubMed ID: 33778929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]